1-(1-甲基-1H-咪唑-4-基)乙-1-醇 | 70702-82-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(1-甲基-1H-咪唑-4-基)乙-1-醇
• 英文名称: 1-(1-methyl-1H-imidazol-4-yl)-ethanol
• 英文别名: 1-(1-Methyl-1H-imidazol-4-yl)-ethanol；1-(1-methylimidazol-4-yl)ethanol
• CAS: 70702-82-8
• 化学式: C₆H₁₀N₂O
• 分子量: 126.158
• InChiKey: QGZWNTJKBUPORC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-甲基咪唑 、 乙醛 生成 1-(1-甲基-1H-咪唑-4-基)乙-1-醇
  参考文献：
  名称：

  JONES II G.; GILOW H. M.; LOW J., J. ORG. CHEM., 1979, 44, NO 16, 2949-2951

  摘要：

  DOI：

文献信息

• Organic compounds
  申请人：Ksander Michael Gary

  公开号：US20070049616A1

  公开（公告）日：2007-03-01

  The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种I式化合物：所述化合物是醛固酮合成酶和芳香化酶的抑制剂，因此可用于治疗由醛固酮合成酶或芳香化酶介导的疾病或疾病。因此，I式化合物可用于治疗低钾血症、高血压、充血性心力衰竭、心房颤动、肾功能衰竭，特别是慢性肾功能衰竭、再狭窄、动脉粥样硬化、X综合征、肥胖、肾病、心肌梗死后、冠心病、炎症、胶原蛋白增生、纤维化如心脏或心肌纤维化以及高血压和内皮功能障碍后的重塑，男性乳房发育过大、骨质疏松症、前列腺癌、子宫内膜异位症、子宫肌瘤、功能性子宫出血、子宫内膜增生、多囊卵巢综合征、不孕症、纤维囊性乳腺疾病、乳腺癌和纤维囊性乳房病。最后，本发明还提供了一种药物组合物。
• Organic Compounds
  申请人：Ksander Gary Michael

  公开号：US20130287789A1

  公开（公告）日：2013-10-31

  The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种化合物I，其为醛固酮合成酶和芳香化酶的抑制剂，因此可用于治疗由醛固酮合成酶或芳香化酶介导的疾病或疾病。因此，化合物I可用于治疗低钾血症、高血压、充血性心力衰竭、心房颤动、肾衰竭，特别是慢性肾衰竭、再狭窄、动脉粥样硬化、X综合症、肥胖症、肾病、心肌梗死后、冠心病、炎症、胶原形成增加、纤维化如心脏或心肌纤维化以及高血压和内皮功能障碍后的重塑、男性乳腺增生、骨质疏松症、前列腺癌、子宫内膜异位症、子宫肌瘤、功能性子宫出血、子宫内膜增生、多囊卵巢综合症、不孕症、纤维囊性乳房病、乳腺癌和纤维囊性乳房病。最后，本发明还提供了一种制药组合物。
• Method for producing optically active compound
  申请人：Yamano Toru

  公开号：US20070276143A1

  公开（公告）日：2007-11-29

  The present invention provides a method for producing an optically active β-hydroxy ester compound represented by the general formula: wherein R 1 represents an optionally substituted hydrocarbon group and the like, R 2 represents a nitrogen-containing heterocyclic group different from R 1 , which is represented by the general formula: wherein the ring may be substituted and the like, R 3 represents an optionally substituted hydrocarbon group and the like, R 4 and R 5 represent, the same or different, a hydrogen atom, a halogen atom and the like, the symbol “*” represents an optically active center, which comprises reacting in the presence of a cinchona alkaloid and the like a compound represented by the general formula: wherein R 1 and R 2 are as defined above with a compound represented by the general formula: wherein R 3 , R 4 and R 5 are as defined above, and X is a halogen atom.

  本发明提供了一种制备光学活性β-羟基酯化合物的方法，该化合物由下述通式表示：其中，R1代表可选取代的碳氢基团等，R2代表与R1不同的含氮杂环基团，其由下述通式表示：其中，环可以取代等，R3代表可选取代的碳氢基团等，R4和R5代表相同或不同的氢原子、卤素原子等，“*”符号代表光学活性中心。该方法包括在奎宁生物碱等存在下，将下述通式表示的化合物：其中，R1和R2如上所定义，与下述通式表示的化合物反应：其中，R3、R4和R5如上所定义，X为卤素原子。
• ALKYNYL ALCOHOLS AS KINASE INHIBITORS
  申请人：Chen Guoqing

  公开号：US20110086834A1

  公开（公告）日：2011-04-14

  Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

  所选化合物对于预防和治疗炎症和炎症性疾病（如NIK介导的疾病）有效。本发明涵盖新的化合物、类似物、前药和其药学上可接受的盐、制药组合物和预防和治疗涉及炎症等疾病和其他疾病或病症的方法。
• UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME
  申请人：Heidelbaugh Todd M.

  公开号：US20120196911A1

  公开（公告）日：2012-08-02

  Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alpha 2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha 2 adrenergic receptors.

  公式1的化合物，其中变量的含义在规范中定义，被用于激活α2肾上腺素受体。公式1的化合物被纳入制药组合物中，并用作哺乳动物，包括人类，治疗对α2肾上腺素受体激动剂治疗敏感的疾病或缓解条件的药物。